F. LaCreta

发表

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

C. Frost, Jessie Wang, S. Nepal, 2012, British journal of clinical pharmacology.

Effect of Multiple‐Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin‐Dependent Diabetes Mellitus Maintained with Diet and Exercise

F. LaCreta, D. Gajjar, G. Kollia, 2000, Pharmacotherapy.

Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

S. Griffen, F. LaCreta, D. Boulton, 2013, Clinical Pharmacokinetics.

Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban.

A. Shenker, C. Frost, Jessie Wang, 2014, British journal of clinical pharmacology.

Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model

F. LaCreta, D. Boulton, T. Leil, 2014, CPT: pharmacometrics & systems pharmacology.

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation

K. Kowalski, B. Cirincione, C. Frost, 2018, CPT: pharmacometrics & systems pharmacology.

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

C. Frost, Jessie Wang, Y. Barrett, 2012, Thrombosis and Haemostasis.

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

C. Frost, Jessie Wang, Y. Barrett, 2013, British journal of clinical pharmacology.

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

A. Shenker, C. Frost, Jessie Wang, 2013, British journal of clinical pharmacology.

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.

F. LaCreta, D. Boulton, C. Patel, 2011, British journal of clinical pharmacology.

Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

F. LaCreta, D. Boulton, S. Kasichayanula, 2013, British journal of clinical pharmacology.

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban

A. Shenker, C. Frost, Jessie Wang, 2015, Clinical Pharmacokinetics.

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

A. Shenker, C. Frost, Jessie Wang, 2018, Clinical pharmacology : advances and applications.

Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study

Z. Wang, C. Frost, Jessie Wang, 2017, Journal of thrombosis and haemostasis : JTH.

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

C. Frost, Jessie Wang, F. LaCreta, 2013, Clinical pharmacology : advances and applications.

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects

C. Frost, Jessie Wang, A. Schuster, 2017, Clinical pharmacology : advances and applications.

Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.

A. D. Rodrigues, F. LaCreta, D. Boulton, 2014, British journal of clinical pharmacology.

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

R. DeFronzo, S. Griffen, F. LaCreta, 2013, Diabetes Care.

of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

R. DeFronzo, S. Griffen, F. LaCreta, 2013 .

Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study.

F. LaCreta, D. Boulton, B. Vakkalagadda, 2016, Clinical therapeutics.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

W. Humphreys, F. LaCreta, D. Boulton, 2013, British journal of clinical pharmacology.

When opportunity met aspirational goals: accelerator MS, microdosing and absolute bioavailability studies.

F. LaCreta, M. Arnold, 2012, Bioanalysis.

Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.

S. Griffen, F. LaCreta, D. Boulton, 2015, Clinical therapeutics.

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

F. LaCreta, D. Boulton, S. Kasichayanula, 2011, Diabetes, obesity & metabolism.

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

S. Griffen, F. LaCreta, D. Boulton, 2011, Diabetes, obesity & metabolism.

Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin

S. Griffen, F. LaCreta, D. Boulton, 2012, Advances in Therapy.

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho‐Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women

X. Xu, F. LaCreta, D. Boulton, 2012, Diabetes, obesity & metabolism.

Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil

G. Hudes, R. Catalano, F. LaCreta, 2004, Cancer Chemotherapy and Pharmacology.

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects

T. Garimella, F. LaCreta, T. Eley, 2017, Drugs in R&D.

Safety and Pharmacokinetics of a Single Oral Dose of Gatifloxacin in Patients with Moderate to Severe Hepatic Impairment

F. LaCreta, G. Kollia, D. Grasela, 2000, Pharmacotherapy.

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery

C. Frost, F. LaCreta, T. Leil, 2014, CPT: pharmacometrics & systems pharmacology.

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies

L. Bergougnan, O. Nicolas, D. Angiolillo, 2011, Clinical pharmacology and therapeutics.

The spontaneous and glutathione S-transferase-mediated reaction of chlorambucil with glutathione.

K. Tew, F. LaCreta, P. Ciaccio, 1990, Cancer communications.

Increased levels of glutathione S-transferase pi transcript as a mechanism of resistance to ethacrynic acid.

K. Tew, F. LaCreta, E. Walsh, 1992, The Biochemical journal.

Purification of glutathione S-transferases from rat liver and Walker 256 mammary carcinoma cells by high-performance liquid chromatography and a glutathione affinity column.

K. Tew, F. LaCreta, J. Olszewski, 1988, Journal of chromatography.

Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets.

R. Tejwani, S. Griffen, F. LaCreta, 2016, International journal of pharmaceutics.

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

F. LaCreta, D. Boulton, T. Leil, 2016, Diabetes, obesity & metabolism.

Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects

F. LaCreta, D. Boulton, M. Pfister, 2011, Diabetes, obesity & metabolism.

Clopidogrel Pharmacodynamics and Pharmacokinetics in the Fed and Fasted State: A Randomized Crossover Study of Healthy Men

F. LaCreta, X. Boulenc, E. Sultan, 2012, Journal of clinical pharmacology.

Lymphocytes from Chronic Lymphocytic Leukemia Patients-Transferase Expression in S Characterization of Glutathione Updated Version

K. Tew, F. LaCreta, R. Silber, 2006 .

Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients.

K. Tew, F. LaCreta, R. Silber, 1990, Cancer research.

SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma.

P. O'dwyer, F. LaCreta, L. Panting, 1993, Biochemical pharmacology.

High-performance liquid chromatographic determination of ethacrynic acid in human plasma.

P. O'dwyer, F. LaCreta, J. Brennan, 1991, Journal of chromatography.

Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.

R. Ozols, K. Tew, P. O'dwyer, 1992, Journal of the National Cancer Institute.

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Mark Lee, F. LaCreta, M. Abutarif, 2021, Clinical and translational science.

Interchangeability of 400‐mg Intravenous and Oral Gatifloxacin in Healthy Adults

F. LaCreta, G. Kollia, D. Grasela, 2000, Pharmacotherapy.

High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine.

R. Ozols, P. O'dwyer, F. LaCreta, 1993, Journal of chromatography.

Phase I trial of buthionine sulfoximine (BSO) in combination with melphalan

R. Ozols, P. O'dwyer, T. Hamilton, 1993 .

Phase I pharmacokinetic study of intraperitoneal etoposide.

P. O'dwyer, N. Rosenblum, F. LaCreta, 1991, Cancer research.

Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects.

S. Badawy, C. Frost, Jessie Wang, 2015, Clinical therapeutics.

Pharmacology and clinical investigation of SR-2508 (etanidazole).

P. O'dwyer, F. LaCreta, 1991, Cancer treatment and research.

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

C. Russo, D. Seiffert, R. Knabb, 2018, British journal of clinical pharmacology.

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

S. Griffen, F. LaCreta, D. Boulton, 2013, Diabetes, obesity & metabolism.

Apixaban Single‐Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration

A. Shenker, C. Frost, Y. Barrett, 2021, Clinical pharmacology in drug development.

The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.

B. Cirincione, F. LaCreta, R. Boyd, 2017, Pharmacoepidemiology and drug safety.

Randomized, blinded, placebo‐ and positive‐controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval

C. Frost, S. Nepal, R. Reeves, 2015, Journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.

C. Frost, Jessie Wang, F. LaCreta, 2014, International journal of clinical pharmacology and therapeutics.

A Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men

F. LaCreta, D. Gajjar, G. Kollia, 2000, Pharmacotherapy.

Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults.

C. Frost, F. LaCreta, R. Frost, 2016, Clinical therapeutics.

Phase I Pharmacokinetic Study of Intraperitoneal Etoposide 1

N. Rosenblum, F. LaCreta, R. Comis, 2006 .

Lack of an Effect of Human Immunodeficiency Virus Coinfection on the Pharmacokinetics of Entecavir in Hepatitis B Virus-Infected Patients

F. LaCreta, D. Grasela, M. Bifano, 2008, Antimicrobial Agents and Chemotherapy.

Age and Gender Effects on the Pharmacokinetics of Gatifloxacin

F. LaCreta, G. Kollia, D. Grasela, 2000, Pharmacotherapy.

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

C. Frost, Jessie Wang, Y. Barrett, 2014, Clinical pharmacology : advances and applications.

Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis.

A. D. Rodrigues, Z. Ouyang, F. LaCreta, 2011, Chemical research in toxicology.

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors

T. Garimella, F. LaCreta, K. Yoshihara, 2020, Clinical pharmacology and therapeutics.

UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions.

F. LaCreta, Naiyu Zheng, Xuewen Ma, 2016, Bioanalysis.

A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

G. Adams, L. Weiner, M. Holmes, 1993, Cancer research.

High-performance liquid chromatographic analysis of fluoropyrimidine nucleosides and fluorouracil in plasma.

F. LaCreta, W. M. Williams, 1987, Journal of chromatography.

Phase I study of the mitomycin C analogue BMS-181174.

A. Harris, P. Philip, K. O'Byrne, 1998, British Journal of Cancer.

Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.

R. Ozols, P. O'dwyer, G. Hudes, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

A. Shenker, C. Frost, Jessie Wang, 2016, American Journal of Cardiovascular Drugs.

Absence of a Pharmacokinetic Interaction Between Entecavir and Adefovir

Robert A. Smith, Robert A. Smith, F. LaCreta, 2007, Journal of clinical pharmacology.

Entecavir Pharmacokinetics, Safety, and Tolerability After Multiple Ascending Doses in Healthy Subjects

Robert A. Smith, Robert A. Smith, F. LaCreta, 2006, Journal of clinical pharmacology.

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

A. Shenker, C. Frost, Jessie Wang, 2015, British journal of clinical pharmacology.

Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid.

K. Tew, F. LaCreta, P. Ciaccio, 1991, Biochemical pharmacology.

Hepatic Fluoropyrimidine Elimination in the Rat Effects of Pyrimidine Nucleoside Phosphorylase Inhibitors on Updated

F. LaCreta, W. M. Williams, B. Warren, 2006 .

Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat.

F. LaCreta, W. M. Williams, B. Warren, 1989, Cancer research.

5-Fluoro-2'-deoxyuridine elimination by the isolated perfused rat liver.

K. Csaky, F. LaCreta, W. M. Williams, 1988, Cancer research.

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.

R. Ozols, P. O'dwyer, D. Martin, 1991, Journal of the National Cancer Institute.

Phase I study of phosphonacetyl-l-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer

R. Ozols, P. O'dwyer, G. Hudes, 2004, Cancer Chemotherapy and Pharmacology.

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside

R. Ozols, P. O'dwyer, J. Colofiore, 1995, Cancer Chemotherapy and Pharmacology.

Phase I trial of fluorouracil modulation by n-phosphonacetyl-l-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer

P. O'dwyer, G. Hudes, F. LaCreta, 2004, Investigational New Drugs.

High-performance liquid chromatographic analysis of N,N',N"-triethylenethiophosphoramide in human plasma.

P. O'dwyer, F. LaCreta, P. Tinsley, 1989, Journal of chromatography.

Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.

R. Ozols, P. O'dwyer, T. Halbherr, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic study of trimetrexate in combination with cisplatin.

S. Litwin, P. O'dwyer, G. Hudes, 1991, Cancer research.

Phase I/pharmacokinetic reevaluation of thioTEPA.

P. Engstrom, S. Litwin, P. O'dwyer, 1991, Cancer research.

Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.

R. Ozols, K. Tew, S. Litwin, 1991, Cancer Research.

Response to Letter to the Editor From Drs. Stöllberger and Finsterer

A. Shenker, C. Frost, Jessie Wang, 2016, Journal of clinical pharmacology.

apixaban Pharmacokinetics and Pharmacodynamics in Subjects With Renal Impairment : 1381212

A. Shenker, C. Frost, Jessie Wang, 2012 .

Bioequivalence of Saxagliptin/Metformin Immediate Release (IR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin IR Tablets in Healthy Adult Subjects

F. LaCreta, D. Boulton, Ming Chang, 2013, Clinical Drug Investigation.

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

R. Perez, S. Johnson, T. Hamilton, 1994, Cancer research.

Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

S. Litwin, P. O'dwyer, F. LaCreta, 1993, British Journal of Cancer.

P. Engstrom, S. Litwin, P. O'dwyer, 1991 .

Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.

P. O'dwyer, G. Hudes, R. Schilder, 1992, Cancer research.

Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma.

W. Curran, S. Evans, G. Hanks, 1991, International journal of radiation oncology, biology, physics.

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

R. Ozols, P. O'dwyer, G. Hudes, 1994, Cancer research.

Clinical, pharmacokinetic and biological studies of topotecan

P. O'dwyer, T. Halbherr, K. Yao, 2004, Cancer Chemotherapy and Pharmacology.

Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma.

J. Kirkwood, J. Willson, D. Haller, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

H. Iwata, K. Tamura, J. Watanabe, 2021, Clinical pharmacology and therapeutics.

Improved chromatographic method for the determination of trimetrexate in urine.

F. LaCreta, P. Tinsley, 1990, Journal of chromatography.

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

Deepak L. Bhatt, E. Vicaut, L. Bergougnan, 2011, Clinical pharmacology and therapeutics.

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion

P. Sager, D. Mager, B. Cirincione, 2017, Journal of clinical pharmacology.

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

F. LaCreta, D. Boulton, M. Pfister, 2011, Clinical therapeutics.

Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

C. Frost, Jessie Wang, F. LaCreta, 2014 .

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy

F. LaCreta, O. Yin, H. Zahir, 2023, Clinical pharmacology in drug development.

Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.

R. Ozols, P. O'dwyer, T. Hamilton, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.

S. Griffen, F. LaCreta, D. Boulton, 2016, Clinical therapeutics.

Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus

F. LaCreta, D. Boulton, G. Tirucherai, 2016, Diabetes, obesity & metabolism.

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects

M. Vetter, F. LaCreta, D. Boulton, 2015, Pharmacology research & perspectives.

Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.

S. Griffen, F. LaCreta, D. Boulton, 2013, Clinical therapeutics.

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Kengo Watanabe, F. LaCreta, H. Zahir, 2022, Clinical Pharmacokinetics.

tolerability, Pharmacokinetics and Pharmacodynamics of Apixaban, Aspirin and Clopidogrel Following Coadministration in Healthy Subjects : 2-54-2000057

C. Frost, S. Nepal, F. LaCreta, 2014 .

lack of Pharmacokinetic Interaction Between Apixaban and Prasugrel in Healthy Subjects : 2-55-2000112

C. Frost, F. LaCreta, J. Pursley, 2014 .

Chromatographic analysis of methylmercaptopurine riboside in human plasma and urine.

P. O'dwyer, F. LaCreta, P. Tinsley, 1991, Journal of chromatography.

Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations

D. Mould, R. Bertz, F. LaCreta, 2016, Clinical Pharmacokinetics.

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics

W. Tap, J. Healey, Li-an Xu, 2022, Journal of clinical pharmacology.

Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach

P. O'dwyer, C. Langer, R. Catalano, 2004, Cancer Chemotherapy and Pharmacology.

Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects

F. LaCreta, D. Boulton, Angela Tang, 2011, Clinical drug investigation.

Dose and flow dependence of 5-fluorouracil elimination by the isolated perfused rat liver.

F. LaCreta, W. M. Williams, B. Warren, 1987, Cancer research.

The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.

B. Cirincione, F. LaCreta, R. Boyd, 2017, Pharmacoepidemiology and drug safety.

Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults.

C. Frost, F. LaCreta, R. Frost, 2016, Clinical therapeutics.

Open‐Label, Nonrandomized Study of the Effects of Gatifloxacin on the Pharmacokinetics of Midazolam in Healthy Male Volunteers

F. LaCreta, G. Kollia, D. Grasela, 2000, Pharmacotherapy.

Clinical Pharmacology: Advances and Applications The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects

C. Frost, Jessie Wang, A. Schuster, 2022 .

Advances and Applications

C. Frost, Jessie Wang, F. LaCreta, 2022 .

Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.

K. Tew, P. O'dwyer, F. LaCreta, 1994, The Journal of pharmacology and experimental therapeutics.